Importantly, large differences in immunogenicity due to antigen origin in malaria pre−erythrocytic stages are overcome by robust recognition by vaccine−induced, antigen-specific effector CD8+ T cells, leading to comparable high levels of protection (Müller et al., 2021). The gene discussed is CD8A; the disease is malaria.